Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Molecular evolution of HRR gene alterations in metastatic prostate cancer

Chinmay Jani • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer

Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, discusses a study on the molecular evolution of homologous recombination repair (HRR) gene alterations in metastatic prostate cancer (mPC), using circulating tumor DNA (ctDNA) profiles. Dynamic changes in HRR mutations, particularly in genes like ATM, BRCA1, and BRCA2, were recorded after treatment with androgen receptor pathway inhibitors, poly ADP-ribose polymerase inhibitors, and taxane chemotherapy. The study also reveals that increased ctDNA burden correlates with poorer overall survival, suggesting these alterations could contribute to treatment resistance. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Chinmay Jani

AI decision support in EGFR-mutant metastatic non-small cell lung cancer
3:12
AI decision support in EGFR-mutant metastatic non-small cell lung cancer
Chinmay Jani • 31 May 2026
Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
2:17
Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
Chinmay Jani • 31 May 2026
Educational impact of a guideline-based hematology-oncology bootcamp curriculum
2:41
Educational impact of a guideline-based hematology-oncology bootcamp curriculum
Chinmay Jani • 31 May 2026
Addressing the escalating impact of alcohol on cancer outcomes
1:11
Addressing the escalating impact of alcohol on cancer outcomes
Chinmay Jani • 2 Jun 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals